Bank of America’s Acrivon Therapeutics ACRV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $24.5K | Sell |
20,617
-7,082
| -26% | -$8.43K | ﹤0.01% | 5994 |
|
|
2025
Q1 | $56.2K | Sell |
27,699
-3,407
| -11% | -$6.92K | ﹤0.01% | 5701 |
|
|
2024
Q4 | $187K | Buy |
31,106
+1,143
| +4% | +$6.88K | ﹤0.01% | 5281 |
|
|
2024
Q3 | $210K | Buy |
29,963
+2,413
| +9% | +$16.9K | ﹤0.01% | 5129 |
|
|
2024
Q2 | $160K | Buy |
27,550
+21,511
| +356% | +$125K | ﹤0.01% | 5193 |
|
|
2024
Q1 | $43.2K | Sell |
6,039
-4,049
| -40% | -$29K | ﹤0.01% | 5696 |
|
|
2023
Q4 | $49.6K | Buy |
10,088
+756
| +8% | +$3.72K | ﹤0.01% | 5666 |
|
|
2023
Q3 | $89.2K | Buy |
9,332
+1,708
| +22% | +$16.3K | ﹤0.01% | 5416 |
|
|
2023
Q2 | $98.8K | Buy |
7,624
+1,768
| +30% | +$22.9K | ﹤0.01% | 5360 |
|
|
2023
Q1 | $74.3K | Buy |
+5,856
| New | +$74.3K | ﹤0.01% | 5567 |
|